Skip to main content

Table 1 Characteristics of patients treated versus not treated with SGLT2i or GLP-1 RA at last follow-up

From: Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

  SGLT2i or GLP-1 RA Standardized Difference (%)a
Yes
n = 2348
No
n = 12,228
Patient factors at enrollment
 Age (years) 56.1 ± 11.5 57.7 ± 12.1 13.8
 Female 42.4% 46.8% 8.8
Education level    26.2
 Primary or none 10.1% 20.0%  
 Secondary 51.6% 49.1%  
 University 37.3% 30.9%  
 Current smoker 18.0% 12.5% 21.5
 Body mass index (kg/m2) 31.8 ± 6.5 28.9 ± 5.8 47.0
 Duration of diabetes 5.6 ± 5.0 5.8 ± 5.3 3.9
 HbA1c (%) 8.3 ± 1.6 8.3 ± 1.7 2.6
 Creatinine (mg/dL) 0.9 ± 1.0 1.0 ± 1.0 5.1
Specialty of Main Investigator    28.3
 Primary care 20.2% 31.4%  
 Endocrinology 74.0% 65.5%  
 Cardiology 4.7% 2.4%  
 Other 1.1% 0.7%  
Region    60.3
 Africa 0.6% 6.5%  
 Americas 18.1% 12.8%  
 Europe 34.1% 21.8%  
 Middle East 11.7% 15.5%  
 Southeast Asia 10.3% 25.4%  
 Western Pacific 25.2% 17.9%  
Comorbidities at last follow-up
 Coronary artery disease 14.8% 10.1% 14.4
 Cerebrovascular disease 2.9% 2.9% 0.2
 Heart failure 7.5% 4.3% 13.2
 Peripheral artery disease 3.4% 3.3% 0.6
 Chronic kidney disease 6.1% 5.1% 4.6
  1. a > 10% difference is considered clinically relevant